2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.
There are many new combination therapies for patients with melanoma, says Postow. In the BRAF-mutant population, there are combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into phase III trials.
Immunotherapy combinations are also moving forward in clinical trials as well, adds Postow. Namely, combinations of IDO blockers and PD-1 agents.
Related Content: